Cargando…
Combined Targeting of NAD Biosynthesis and the NAD-dependent Transcription Factor C-terminal Binding Protein as a Promising Novel Therapy for Pancreatic Cancer
Cancer therapies targeting metabolic derangements unique to cancer cells are emerging as a key strategy to address refractory solid tumors such as pancreatic ductal adenocarcinomas (PDAC) that exhibit resistance to extreme nutrient deprivation in the tumor microenvironment. Nicotinamide adenine dinu...
Autores principales: | Dcona, M. Michael, Chougoni, Kranthi Kumar, Dcona, Diana T., West, Jacqueline L., Singh, Sahib J., Ellis, Keith C., Grossman, Steven R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549224/ https://www.ncbi.nlm.nih.gov/pubmed/37707363 http://dx.doi.org/10.1158/2767-9764.CRC-22-0521 |
Ejemplares similares
-
Coordinate transcriptional regulation of ErbB2/3 by C-terminal binding protein 2 signals sensitivity to ErbB2 inhibition in pancreatic adenocarcinoma
por: Chougoni, Kranthi Kumar, et al.
Publicado: (2023) -
CtBP- an emerging oncogene and novel small molecule drug target: Advances in the understanding of its oncogenic action and identification of therapeutic inhibitors
por: Dcona, M. Michael, et al.
Publicado: (2017) -
Extraction of high-quality RNA from mouse pancreatic tumors
por: Chougoni, Kranthi Kumar, et al.
Publicado: (2020) -
NAD
(+) biosynthesis, aging, and disease
por: Johnson, Sean, et al.
Publicado: (2018) -
Nicotinaldehyde, a Novel Precursor of NAD Biosynthesis, Abrogates the Anti-Cancer Activity of an NAD-Lowering Agent in Leukemia
por: Matsumoto, Saki, et al.
Publicado: (2023)